Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 28, 2026, 5:20 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 673–696 of 1,356 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Resolution Clear all
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers Results available

The Effect of Intravitreal Ranibizumab on Visual Acuity and Hard Exudate Resolution in the Treatment of Diabetic Macular Edema With Center Involved Edema and Lipid Exudates

NCT02448446
View directory record Official record
Conditions
Diabetic Macular Edema, Hard Lipid Exudates
Interventions
ranibizumab 0.3mg
Drug
Lead sponsor
South Coast Retina Center; Carson, McBeath, Boswell, Inc.
Other
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2018
U.S. locations
4
States / cities
Huntington Beach, California • Long Beach, California • Santa Monica, California + 1 more
Source: ClinicalTrials.gov public record
Updated Jul 8, 2021 · Synced Oct 28, 2026, 5:20 AM EDT
Completed Phase 1Phase 2 Interventional

Safety/Efficacy Study: OPA-6566 Ophthalmic Solution in Subjects With Primary Open-Angle Glaucoma or Ocular Hypertension

NCT01410188
View directory record Official record
Conditions
Primary Open-angle Glaucoma, Ocular Hypertension
Interventions
OPA-6566, Placebo, Latanoprost
Drug
Lead sponsor
Kubota Vision Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
160 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
9
States / cities
Artesia, California • Glendale, California • Roswell, Georgia + 6 more
Source: ClinicalTrials.gov public record
Updated Mar 11, 2014 · Synced Oct 28, 2026, 5:20 AM EDT
Completed Not applicable Interventional Results available

Prospective Evaluation of a Surgical Solution for Breast Cancer-Associated Lymphedema

NCT02734979
View directory record Official record
Conditions
Lymphedema, Edema
Interventions
Biobridge and lymph node transfer
Device
Lead sponsor
Stanford University
Other
Eligibility
18 Years to 75 Years
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Oct 27, 2022 · Synced Oct 28, 2026, 5:20 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers

Safety and Efficacy Study of BRIMOCHOL™ PF and Carbachol PF in Subjects With Emmetropic Phakic and Pseudophakic Presbyopia

NCT05135286
View directory record Official record
Conditions
Presbyopia
Interventions
BRIMOCHOL™ PF, Carbachol PF, Vehicle
Drug
Lead sponsor
Visus Therapeutics
Other
Eligibility
45 Years to 80 Years
Enrollment
629 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2025
U.S. locations
42
States / cities
Chandler, Arizona • Phoenix, Arizona • Sun City, Arizona + 39 more
Source: ClinicalTrials.gov public record
Updated Aug 6, 2025 · Synced Oct 28, 2026, 5:20 AM EDT
Completed Not applicable Interventional

Tap Water Versus Normal Saline for Wound Irrigation

NCT01564342
View directory record Official record
Conditions
Wound Infection Rate
Interventions
wound irrigation with study fluid
Procedure
Lead sponsor
Stanford University
Other
Eligibility
12 Months and older
Enrollment
660 participants
Timeline
1994 – 1996
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Mar 27, 2012 · Synced Oct 28, 2026, 5:20 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Comparative Bioavailability Study of Morphine Sulfate Immediate Release and Controlled Release

NCT00994383
View directory record Official record
Conditions
Pain
Interventions
morphine sulfate
Drug
Lead sponsor
Roxane Laboratories
Industry
Eligibility
18 Years to 45 Years
Enrollment
36 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Jan 23, 2018 · Synced Oct 28, 2026, 5:20 AM EDT
Completed Not applicable Interventional Results available

Evaluating an eHealth Solution for Screening in Pediatric Care

NCT04506294
View directory record Official record
Conditions
Pain, Stress Disorders, Post-Traumatic
Interventions
eScreen system
Behavioral
Lead sponsor
Children's Hospital of Philadelphia
Other
Eligibility
8 Years to 17 Years
Enrollment
320 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
2
States / cities
Lexington, Kentucky • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jun 26, 2024 · Synced Oct 28, 2026, 5:20 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

Safety and Efficacy Study of the NRT CQSS2 System for Smoking Cessation in Treatment-Seeking Subjects

NCT03178422
View directory record Official record
Conditions
Smoking Cessation
Interventions
CQSS2, NicoDerm CQ Patch
Drug
Lead sponsor
Chrono Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
220 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017
U.S. locations
5
States / cities
Mobile, Alabama • Tempe, Arizona • Lexington, Kentucky + 2 more
Source: ClinicalTrials.gov public record
Updated Dec 4, 2017 · Synced Oct 28, 2026, 5:20 AM EDT
Completed Not applicable Interventional Results available

2-Hour Dispensing Evaluation of Samfilcon A Lenses With EPG01 Packaging Solution Compared to Commercially Available B+L Ultra Lenses

NCT05126953
View directory record Official record
Conditions
Contact Lens Wearer
Interventions
samfilcon A Lenses with EPG01 Packaging Solution, Commercially Available B+L Ultra Lenses
Device
Lead sponsor
Bausch & Lomb Incorporated
Industry
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021
U.S. locations
1
States / cities
Rochester, New York
Source: ClinicalTrials.gov public record
Updated Jul 20, 2025 · Synced Oct 28, 2026, 5:20 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

South Carolina WIC Telehealth Solution

NCT05887869
View directory record Official record
Conditions
Telehealth, Nutrition Education, Breast Feeding, Dietary Intake, WIC
Interventions
Telehealth solution
Behavioral
Lead sponsor
Tufts University
Other
Eligibility
18 Years and older · Female only
Enrollment
50 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 31, 2024 · Synced Oct 28, 2026, 5:20 AM EDT
Terminated Phase 3 Interventional Results available

Efficacy and Safety of GWP42003-P Oral Solution in Children With Epilepsy With Myoclonic-atonic Seizures

NCT05288283
View directory record Official record
Conditions
Seizures Associated With EMAS
Interventions
GWP42003-P, Placebo
Drug
Lead sponsor
Jazz Pharmaceuticals
Industry
Eligibility
1 Year to 18 Years
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
10
States / cities
Birmingham, Alabama • Sacramento, California • Atlanta, Georgia + 7 more
Source: ClinicalTrials.gov public record
Updated Feb 3, 2025 · Synced Oct 28, 2026, 5:20 AM EDT
Completed Phase 2 Interventional Results available

Comparison of Therapeutic Regimens for Scleroderma Interstitial Lung Disease (The Scleroderma Lung Study II)

NCT00883129
View directory record Official record
Conditions
Scleroderma, Interstitial Lung Disease
Interventions
Mycophenolate mofetil, Cyclophosphamide, Placebo
Drug
Lead sponsor
Michael Roth
Other
Eligibility
18 Years and older
Enrollment
142 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2015
U.S. locations
14
States / cities
Los Angeles, California • San Francisco, California • Denver, Colorado + 10 more
Source: ClinicalTrials.gov public record
Updated Feb 10, 2017 · Synced Oct 28, 2026, 5:20 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Evaluating the Efficacy and Compatibility of Efinaconazole 10% Solution (Jublia) for the Treatment of Toenail Onychomycosis in Patients Wearing Toenail Polish Compared to Those Without Polish

NCT03110029
View directory record Official record
Conditions
Onychomycosis of Toenail
Interventions
Efinaconazole 10% Topical Application Solution [JUBLIA], Application of Nail Polish
Drug · Other
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
19 Years to 70 Years · Female only
Enrollment
13 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2018
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Jun 27, 2019 · Synced Oct 28, 2026, 5:20 AM EDT
Completed Phase 2 Interventional Results available

A Study of the Safety, Tolerability, and Efficacy of Topical SM04554 Solution in Male Subjects With Androgenetic Alopecia (AGA)

NCT02275351
View directory record Official record
Conditions
Androgenetic Alopecia
Interventions
Topical SM04554 solution, Topical vehicle solution
Drug
Lead sponsor
Biosplice Therapeutics, Inc.
Industry
Eligibility
18 Years to 55 Years · Male only
Enrollment
302 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
24
States / cities
Encinitas, California • San Diego, California • New Haven, Connecticut + 20 more
Source: ClinicalTrials.gov public record
Updated Oct 21, 2026 · Synced Oct 28, 2026, 5:20 AM EDT
Completed Phase 3 Interventional Results available

Long-Term Safety of Latanoprostene Bunod Ophthalmic Solution 0.024% in Japanese Subjects With OAG or OHT

NCT01895972
View directory record Official record
Conditions
Glaucoma, Ocular Hypertension
Interventions
Latanoprostene bunod
Drug
Lead sponsor
Bausch & Lomb Incorporated
Industry
Eligibility
20 Years and older
Enrollment
130 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
1
States / cities
Bridgewater, New Jersey
Source: ClinicalTrials.gov public record
Updated Jul 26, 2018 · Synced Oct 28, 2026, 5:20 AM EDT
Recruiting No phase listed Observational

Extracorporeal Photopheresis in Sezary Syndrome

NCT05157581
View directory record Official record
Conditions
Sezary Syndrome
Interventions
Extracorporeal photopheresis (ECP), Methoxsalen Injection
Device · Drug
Lead sponsor
Oleg E. Akilov, MD, PhD
Other
Eligibility
18 Years to 100 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
3
States / cities
Atlanta, Georgia • Baltimore, Maryland • Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Dec 30, 2025 · Synced Oct 28, 2026, 5:20 AM EDT
Completed Phase 3 Interventional Results available

A Study of A-101 Topical Solution for the Treatment of Common Warts

NCT03691831
View directory record Official record
Conditions
Common Wart
Interventions
Active, Vehicle
Drug · Other
Lead sponsor
Aclaris Therapeutics, Inc.
Industry
Eligibility
2 Years and older
Enrollment
502 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
24
States / cities
Glendale, Arizona • Fort Smith, Arkansas • Encinitas, California + 21 more
Source: ClinicalTrials.gov public record
Updated Oct 27, 2020 · Synced Oct 28, 2026, 5:20 AM EDT
Completed Phase 2 Interventional

Evaluating the Use of Photodynamic Therapy to Treat Facial Cutaneous Squamous Cell Carcinoma in Situ (isSCC)

NCT06159842
View directory record Official record
Conditions
Facial Cutaneous Squamous Cell Carcinoma in Situ
Interventions
Aminolevulinic Acid 20% Topical Solution with Blue Light
Combination Product
Lead sponsor
The Center for Clinical and Cosmetic Research
Other
Eligibility
18 Years and older
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
1
States / cities
Aventura, Florida
Source: ClinicalTrials.gov public record
Updated Feb 12, 2025 · Synced Oct 28, 2026, 5:20 AM EDT
Completed No phase listed Observational

Correlation of Lung Biopsy, BAL, and High Resolution CT Scan in Lung Transplantation

NCT00528853
View directory record Official record
Conditions
Bronchiolitis Obliterans Syndrome
Interventions
Not listed
Lead sponsor
University of Chicago
Other
Eligibility
18 Years to 65 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Aug 19, 2016 · Synced Oct 28, 2026, 5:20 AM EDT
Terminated Phase 3 Interventional

CIS001 Extension Study of Cyclosporine Inhalation Solution

NCT00938236
View directory record Official record
Conditions
Lung Transplant
Interventions
Cyclosporine Inhalation Solution (CIS)
Drug
Lead sponsor
APT Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
15
States / cities
Los Angeles, California • San Francisco, California • Stanford, California + 12 more
Source: ClinicalTrials.gov public record
Updated Sep 17, 2012 · Synced Oct 28, 2026, 5:20 AM EDT
Completed Phase 3 Interventional Results available

Inhaled Amikacin Solution BAY41-6551 as Adjunctive Therapy in the Treatment of Gram-Negative Pneumonia

NCT01799993
View directory record Official record
Conditions
Pneumonia, Bacterial
Interventions
Amikacin Inhalation Solution (BAY41-6551), Aerosolized Placebo
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years and older
Enrollment
725 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
32
States / cities
Birmingham, Alabama • Mobile, Alabama • Phoenix, Arizona + 27 more
Source: ClinicalTrials.gov public record
Updated Jul 23, 2018 · Synced Oct 28, 2026, 5:20 AM EDT
Completed Phase 2 Interventional

Tiotropium Bromide Inhalation Solution in Subjects With Chronic Obstructive Pulmonary Disease

NCT04780984
View directory record Official record
Conditions
Chronic Obstructive Pulmonary Disease (COPD)
Interventions
Tiotropium bromide inhalation solution, Placebo
Drug
Lead sponsor
Nephron Pharmaceuticals Corporation
Industry
Eligibility
40 Years to 80 Years
Enrollment
116 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
Rock Hill, South Carolina
Source: ClinicalTrials.gov public record
Updated May 10, 2021 · Synced Oct 28, 2026, 5:20 AM EDT
Terminated Phase 3 Interventional Results available

Methoxsalen and Extracorporeal Photopheresis (ECP) for the Treatment of Pediatric Participants With Steroid Refractory Acute Graft Versus Host Disease

NCT02524847
View directory record Official record
Conditions
Steroid Refractory Acute Graft Versus Host Disease
Interventions
Methoxsalen, Extracorporeal Photopheresis (ECP)
Drug · Procedure
Lead sponsor
Therakos, Inc., a Mallinckrodt Company
Industry
Eligibility
1 Year to 21 Years
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
17
States / cities
Phoenix, Arizona • Los Angeles, California • New Haven, Connecticut + 13 more
Source: ClinicalTrials.gov public record
Updated Sep 11, 2020 · Synced Oct 28, 2026, 5:20 AM EDT
Completed Phase 4 Interventional Results available

A Clinical Study to Investigate if a Single Dose of an Approved Drug Product (Glycopyrrolate Inhalation Solution) Reduces Trapped Air in the Lungs of Participants With Chronic Obstructive Pulmonary Disease.

NCT04155047
View directory record Official record
Conditions
Chronic Obstructive Pulmonary Disease (COPD)
Interventions
Glyocopyrrolate Inhalation Solution administered by Magnair, Placebo administered by Magnair
Combination Product · Drug
Lead sponsor
Sunovion Respiratory Development Inc.
Industry
Eligibility
40 Years to 99 Years
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
1
States / cities
Saint Charles, Missouri
Source: ClinicalTrials.gov public record
Updated May 10, 2021 · Synced Oct 28, 2026, 5:20 AM EDT